Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04939311
Other study ID # VITAL HIV
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date July 1, 2022
Est. completion date July 1, 2027

Study information

Verified date September 2022
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a double blinded, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo for anti-inflammation in HIV-infected subjects.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 1, 2027
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Documented HIV infection - On continuous antiretroviral therapy and virologically suppressed HIV infection for =12 weeks prior to study entry - CD4 T-cell count > 350 cells/mm3 - Male or female between the ages = 40 years of age to <=75 - Documented cardiovascular disease (1. Prior myocardial infarction, 2. History of percutaneous coronary intervention, 3. History of coronary artery bypass graft OR 4. Angiographic evidence of >50% stenosis in at least one coronary artery] OR 1 CVD risk factor (T2DM, current smoking, hypertension, dyslipidemia, hsCRP=2mg/L, family history) - TBR of >1.6 of the MDS of the carotid/aorta at baseline. This baseline arterial TBR cutoff excludes the rare individual that lacks appreciable arterial inflammation. It is notable that while 5-10% of uninfected individuals will have lower TBRs, it is rare that an HIV infected individual will fall below this range. - Female subjects must either be of non-childbearing potential as defined by menopause with amenorrhea for >2 years, bilateral oophorectomy, or agree to use adequate contraception throughout the study and for at least one month following termination and have a negative pregnancy test at screening prior to the first dose of drug. - Males must use at least one method of contraception throughout the study. Exclusion Criteria: - Pregnant/nursing women - Uncontrolled hypertension or diabetes requiring insulin - AST/ALT or alkaline phosphatase >2x ULN - Cancer within the last 5 years with exception of squamous cell carcinoma and basal cell carcinoma - Nephrotic syndrome or eGFR <60 mL/min/1.73m2 - Cytopenias which include 1) WBC <3.5 x103/uL 2) Platelet <120 x103/uL 3) ANC <1.5 x103/uL, and absolute lymphocytes <0.8 x 103/uL - Anemia as fined by <10 g/dL - Evidence of tuberculosis infection at screening within 30 days prior to screening. - Family history of long QT syndrome, using medication that prolongs QT internal, OR evidence of prolonged QT of >470 msec as evidenced by ECG - Acute systemic infection within 30 days - On additional immunosuppressant or immunomodulatory therapies

Study Design


Intervention

Drug:
VB-201
One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.
Placebo
One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.

Locations

Country Name City State
United States Zuckerberg San Francisco General Hospital San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
Priscilla Hsue, MD University of California, Los Angeles, University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in non-calcified plaque progression Change in non-calcified plaque progression from baseline to week 52 as assessed by Coronary Computed Tomography Angiography (Coronary CTA) 1 year (Baseline and Week 52)
Other Change in high risk plaque Change in high-risk plaque from baseline to week 52 as assessed by Coronary Computed Tomography Angiography (Coronary CTA) 1 year (Baseline and Week 52)
Other Incidence of new lesions Incidence of new lesions from baseline to week 52 as assessed by Coronary Computed Tomography Angiography (Coronary CTA) 1 year (Baseline and Week 52)
Primary Change in Target-to-background ratio (TBR) Change in Target-to-background ratio (TBR) from baseline to follow-up study at 52 weeks as assessed by Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) 1 year (Baseline and Week 52)
Secondary Change in high sensitivity C-reactive protein (hs-CRP) in mg/L Change in hs-CRP from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in Interleukin-6 (IL-6) in pg/mL Change in IL-6 from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in soluble cluster of differentiation (sCD163) ng/mL Change in sCD163 from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in Lipoprotein (a) [Lp(a)] in mg/dL Change in Lp(a) from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in Lipoprotein-associated Phospholipase A2 (Lp-PLA2) in ng/mL Change in Lp-PLA2 from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in D-Dimer (ng/mL) Change in D-Dimer from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in Markers of Immune Activation Change in Co-expression of HLA-DR/CD38 on T-cells from baseline to week 24 and baseline to week 52 as measured by blood collection 1 year (Change from baseline to week 24 and baseline to week 52)
Secondary Change in Monocyte Activation Change in Co-expression of CD14/CD16 on Monocytes from baseline to week 24 and baseline to week 52 1 year (Change from baseline to week 24 and baseline to week 52)
See also
  Status Clinical Trial Phase
Recruiting NCT03995979 - Inflammation and Protein Restriction N/A
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT04856748 - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed NCT05529693 - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Active, not recruiting NCT06065241 - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals. N/A
Active, not recruiting NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Not yet recruiting NCT06134076 - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota N/A
Not yet recruiting NCT05910489 - Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect